In-Person Access Only | 4.00 CME Credits

Please read: All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $25 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team. Industry representatives—defined as any individual who is employed by, contracted with, owns, or represents a drug, device, diagnostic, or other healthcare-related commercial entity, regardless of clinical credentials or licensure—are not permitted to attend Total Health events as general attendees. Members of industry must contact exhibits@totalhealthoncology.com

The University of Kansas Cancer Center Breast Cancer Year in Review is a condensed review of new data and advances published throughout the year and presented at key oncology meetings. It gives healthcare providers the opportunity to learn about the latest advances in oncology education and translate science into better patient care. This accredited meeting is hosted as an in-person conference only with on-demand access for registered attendees

Conference Agenda
Saturday, February 21, 2026

8:00 AM
Registration Check-In and Breakfast

8:20 AM
Conference Welcome
Priyanka Sharma, MD | University of Kansas Cancer Center - Program Chair
Jennifer Klemp, PhD | University of Kansas Cancer Center - Program Chair

8:25 AM
NON CME PRESENTATION - Daiichi Sankyo

9:10 AM
Program Chair Remarks
Priyanka Sharma, MD | University of Kansas Cancer Center - Program Chair
Jennifer Klemp, PhD | University of Kansas Cancer Center - Program Chair

9:15 AM
Treatment Updates for Early and Metastatic TNBC
Rita Nanda, MD | University of Chicago

9:40 AM
Role of CtDNA Monitoring in Management of Early and Advanced Breast Cancer
Carlos Barcenas, MD, MSc | MD Anderson Cancer Center

10:05 AM
Break and Exhibits

10:20 AM
Fine-Tuning Post CDK4/6 Inhibitor Endocrine and Targeted Therapy for Hormone Positive Metastatic Breast Cancer
Erica Mayer, MD, MPH | Dana Farber Cancer Institute

10:45 AM
Monday Morning Practice Implications: Q&A and Case Discussion
Rita Nanda, MD | University of Chicago
Carlos Barcenas, MD, MSc | MD Anderson Cancer Center
Erica Mayer, MD, MPH | Dana Farber Cancer Institute
Pavan Reddy, MD | University of Kansas Cancer Center
Julia White, MD | University of Kansas Cancer Center

11:30 AM
Break and Exhibits

11:40 AM
Non CME Presentation

12:25 PM
Optimizing Radiotherapy for Patients with High-Risk Early-Stage Breast Cancer
Gaorav Gupta, MD | UNC School of Medicine

12:50 PM
Recent Advances in Management of Early Stage HER2 Positive Breast Cancer
Mark Pegram, MD | Stanford Medicine

1:15 PM
Break and Exhibits

1:30 PM
Mitigating Endocrine Therapy Associated Toxicities
Norah Lynn Henry, MD, PhD | University of Michigan

1:55 PM
Monday Morning Practice Implications: Q&A and Case Discussion
Gaorav Gupta, MD | UNC School of Medicine
Mark Pegram, MD | Stanford Medicine
Norah Lynn Henry, MD, PhD | University of Michigan
Anne O’Dea, MD | University of Kansas Cancer Center

2:40 PM
Adjourn

Agenda Subject To Change. All times are CST.

• Learning Objectives

  • Determine best application of new targeted therapies in patients with early stage and metastatic disease

  • Discuss the advances in systemic therapy likely to change current practices for treatment of breast cancer

  • Know how to utilize genomic tools for systemic therapy decision making and prediction of treatment response.

  • Be familiar with germ-line genetic testing options for hereditary breast cancer, including advantages and disadvantages of extended panel testing

  • Evaluate local therapy options for operable breast cancer depending on stage, and the use of neoadjuvant therapy

  • Identify evidence-based recommendations for decreasing symptoms and improving quantity and/or quality of life in survivors

• Accreditation Information | 4.00 CME Credits

  In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

  Nurses (ANCC) Credit Designation

  Amedco LLC designates this activity for a maximum of TBD ANCC contact hours.

  Physicians (ACCME) Credit Designation

  Amedco LLC designates this live activity for a maximum of 4.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

  Amedco LLC designates this activity for a maximum of 4.00 knowledge-based CPE contact hours.

  NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

• What to Expect | In-Person Learners

  • Free registration for all healthcare providers

  • Expert sessions that present the most clinically relevant data, research, and clinical strategies

  • Real-time discussion and debate

  • Networking with peers, colleagues, and medical professionals

  • Access to the latest industry information and resources

  • Catered meals through-out the program